Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

News in Brief

Maintenance Olaparib New Standard in Pancreatic Cancer?

DOI: 10.1158/2159-8290.CD-NB2019-065 Published August 2019
  • Article
  • Info & Metrics
Loading

Maintenance olaparib (Lynparza; AstraZeneca) is likely to become a new treatment option for patients with metastatic pancreatic cancer and germline BRCA mutations following platinum-based chemotherapy, based on findings presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, IL, on June 2 and simultaneously published in The New England Journal of Medicine. In the phase III POLO trial, olaparib significantly extended progression-free survival (PFS) and median duration of response (DoR) compared with a placebo, and it did not adversely affect quality of life.

“Metastatic pancreatic cancer is a dismal disease—even with modern chemotherapy regimens, patients generally live less than a year,” and second-line treatment options are limited, said senior author Hedy Kindler, MD, of the University of Chicago, who presented the results. However, the 4% to 7% of patients with germline BRCA mutations are more responsive to first-line platinum-based chemotherapy, and a single-arm phase II trial, published online in 2014, suggested that these patients may also respond to the PARP inhibitor olaparib.

Kindler and her colleagues designed the phase III POLO trial to test olaparib as a maintenance therapy in patients with metastatic disease who had germline BRCA1/2 mutations following successful treatment with platinum-based chemotherapy. In total, 154 patients were assigned 3:2 to receive olaparib or a placebo.

Patients treated with the drug had a median PFS of 7.4 months and an objective response rate of 23.1%, compared with 3.8 months and 11.5% in patients receiving a placebo. Patients on olaparib also had a median DoR of 24.9 months, compared with 3.7 months in patients on a placebo, a finding that Kindler called “truly remarkable.” Interim survival data did not significantly differ between arms; final survival data are not yet available.

Adverse effects classified as grade 3 or higher occurred in 40% of patients taking olaparib and caused 5.5% to stop treatment, compared with 23% and 1.7% of those receiving a placebo. Kindler noted that the side-effect profile was similar to that seen with olaparib in other tumor types. Patients in both arms reported a similar quality of life.

“Our results are the first from a phase III trial to validate a targeted treatment in a biomarker-selected population of pancreatic cancer patients,” Kindler said, adding that she thinks maintenance olaparib could become a new standard of care. A future goal, she said, is to identify more patients with pancreatic cancer who might benefit from maintenance olaparib—ongoing trials are investigating the drug in patients with somatic BRCA mutations.

“This is a really huge step forward,” said Suzanne Cole, MD, of The University of Texas Southwestern Medical Center in Dallas, who was not involved in the trial. “This is the first time that a targeted medication has been successful in stopping the growth of metastatic pancreatic cancer in people who carry the BRCA mutation.”

However, Wells Messersmith, MD, of the University of Colorado Comprehensive Cancer Center in Aurora, who was also not connected to the study, noted that the lack of survival benefit thus far suggests that although olaparib should become an option for patients with germline BRCA mutations, “it's very reasonable to continue platinum-based therapies,” especially considering the drug's high cost.

Cole and Messersmith agree that the results highlight the need for more widespread genetic testing, as is recommended by guidelines recently released by the National Comprehensive Cancer Network. “Now that we have a targeted medication that can benefit patients who have a BRCA mutation … it is our duty to search for this genetic mutation in all patients with metastatic pancreatic cancer,” Cole said. –Catherine Caruso

  • ©2019 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 9 (8)
August 2019
Volume 9, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Maintenance Olaparib New Standard in Pancreatic Cancer?
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Maintenance Olaparib New Standard in Pancreatic Cancer?
Cancer Discov August 1 2019 (9) (8) OF6; DOI: 10.1158/2159-8290.CD-NB2019-065

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Maintenance Olaparib New Standard in Pancreatic Cancer?
Cancer Discov August 1 2019 (9) (8) OF6; DOI: 10.1158/2159-8290.CD-NB2019-065
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • ADC Successfully Targets Urothelial Cancer
  • Break Through Cancer Launches with $250M Pledge
  • By The Numbers: Novel Drugs Approved by the FDA, 2011-2020
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement